Literature DB >> 22358446

T-cell receptor gene rearrangements and expression in normal human large granular lymphocytes (LGL) and their pathological expansions.

A Pirelli1, P Allavena, A Rambaldi, M Di Bello, P Pirovano, F Peccatori, A Mantovani.   

Abstract

The lineage to which normal large granular lymphocytes/natural killer (LGL/NK) cells belong is controversial; in fact they share some surface markers and functional activities with monocytes, but also with T lymphocytes. The relationship of LGL to the T cell lineage by analysis with the T cell receptor (T-rec) gene has been investigated. Pure preparations of human LGL and their CD11(+) CD8(-) and CD11(-) CD8(+) subsets had the Tβ gene in its unrearranged germline configuration. Expression of Tα and Tβ genes was not detectable. The organization of Tγ gene, which is of particular importance because it occurs early in T cell ontogeny, was also found in its germline configuration.A rare type of lymphoproliferative disorder, termed Tγ-LPD, is characterized by expansion of cells very similar to LGL for morphology, phenotype, and functional activity. Of 17 patients with Tγ-LPD studied for T-rec rearrangement, 15 displayed rearrangement of Tβ and Tγ loci and were CD3+ (14/15 had monoclonal rearrangement), while 2 cases were in germline configuration and were CD3-. Similarly to very small subsets of CD3+ LGL recently described, most Tγ-LPD cases are CD3+ and have T-rec genes rearranged. These data suggest that either a subset of LGL or a particular step of differentiation may be related to the T cell lineage; they also demonstrate that, in contrast to previous views, most TγLPD are monoclonal, presumably neoplastic, lymphoproliferative disorders.

Entities:  

Year:  1987        PMID: 22358446     DOI: 10.1007/BF00351128

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  8 in total

1.  Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones.

Authors:  J Ritz; T J Campen; R E Schmidt; H D Royer; T Hercend; R E Hussey; E L Reinherz
Journal:  Science       Date:  1985-06-28       Impact factor: 47.728

2.  Gene rearrangement in cells with natural killer activity and expression of the beta-chain of the T-cell antigen receptor.

Authors:  Y Yanagi; N Caccia; M Kronenberg; B Chin; J Roder; D Rohel; T Kiyohara; R Lauzon; B Toyonaga; K Rosenthal
Journal:  Nature       Date:  1985 Apr 18-24       Impact factor: 49.962

Review 3.  Human natural killer cells: biologic and pathologic aspects.

Authors:  G Trinchieri; B Perussia
Journal:  Lab Invest       Date:  1984-05       Impact factor: 5.662

4.  Rearrangements of T-cell receptor gene YT35 in human DNA from thymic leukaemia T-cell lines and functional T-cell clones.

Authors:  B Toyonaga; Y Yanagi; N Suciu-Foca; M Minden; T W Mak
Journal:  Nature       Date:  1984 Sep 27-Oct 3       Impact factor: 49.962

5.  Two tandemly organized human genes encoding the T-cell gamma constant-region sequences show multiple rearrangement in different T-cell types.

Authors:  M P Lefranc; T H Rabbitts
Journal:  Nature       Date:  1985 Aug 1-7       Impact factor: 49.962

6.  T cell receptor beta chain gene rearrangements in lymphoproliferative disorders of large granular lymphocytes/natural killer cells.

Authors:  A Rambaldi; P G Pelicci; P Allavena; D M Knowles; S Rossini; R Bassan; T Barbui; R Dalla-Favera; A Mantovani
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

7.  Expression of the NKTa clonotype in a series of human natural killer clones with identical cytotoxic specificity.

Authors:  R E Schmidt; G T Bartley; S S Lee; J F Daley; H D Royer; H Levine; E L Reinherz; S F Schlossman; J Ritz
Journal:  J Exp Med       Date:  1986-04-01       Impact factor: 14.307

8.  Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen).

Authors:  L L Lanier; T J Kipps; J H Phillips
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.